NO20081365L - Ny krystallinsk form av et pyridazino[4,5-b]indolderivat - Google Patents

Ny krystallinsk form av et pyridazino[4,5-b]indolderivat

Info

Publication number
NO20081365L
NO20081365L NO20081365A NO20081365A NO20081365L NO 20081365 L NO20081365 L NO 20081365L NO 20081365 A NO20081365 A NO 20081365A NO 20081365 A NO20081365 A NO 20081365A NO 20081365 L NO20081365 L NO 20081365L
Authority
NO
Norway
Prior art keywords
pyridazino
crystalline form
new crystalline
indole derivative
indole
Prior art date
Application number
NO20081365A
Other languages
English (en)
Inventor
John D Higgins
William L Rocco
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081365(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20081365L publication Critical patent/NO20081365L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet en ny krystallinsk form av 7-klor-N,N-5-trimetyl-4-okso-3-fenyl-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid, fremgangsmåter for fremstilling av nevnte krystallinske form av 7-klor-N,N-5-trimetyl-4-okso-3-fenyl-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid, preparater omfattende nevnte form i blanding med ett eller flere farmasøytisk akseptable hjelpestoffer og anvendelser av samme.
NO20081365A 2005-08-29 2008-03-14 Ny krystallinsk form av et pyridazino[4,5-b]indolderivat NO20081365L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative

Publications (1)

Publication Number Publication Date
NO20081365L true NO20081365L (no) 2008-04-03

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081365A NO20081365L (no) 2005-08-29 2008-03-14 Ny krystallinsk form av et pyridazino[4,5-b]indolderivat

Country Status (32)

Country Link
US (1) US7683062B2 (no)
EP (1) EP1924585B1 (no)
JP (1) JP5063600B2 (no)
KR (2) KR20080050577A (no)
CN (1) CN101253176B (no)
AR (1) AR057099A1 (no)
AT (1) ATE531717T1 (no)
AU (1) AU2006285142B2 (no)
BR (1) BRPI0615259A2 (no)
CA (1) CA2619284C (no)
CR (1) CR9723A (no)
CY (1) CY1112317T1 (no)
DK (1) DK1924585T3 (no)
EA (1) EA014164B1 (no)
EC (1) ECSP088209A (no)
ES (1) ES2375841T3 (no)
HK (1) HK1123794A1 (no)
HR (1) HRP20120073T1 (no)
IL (1) IL189276A (no)
MA (1) MA30000B1 (no)
NO (1) NO20081365L (no)
NZ (1) NZ566087A (no)
PL (1) PL1924585T3 (no)
PT (1) PT1924585E (no)
RS (1) RS52318B (no)
SI (1) SI1924585T1 (no)
TN (1) TNSN08059A1 (no)
TW (1) TW200813060A (no)
UA (1) UA91716C2 (no)
UY (1) UY29771A1 (no)
WO (1) WO2007027525A1 (no)
ZA (1) ZA200801890B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678124C (en) * 2003-11-17 2014-10-07 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
BRPI0617947A2 (pt) * 2005-10-31 2011-08-09 Janssen Pharmaceutica Nv processos para a preparação de derivados de piperazinil e diazapanil benzamida
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
CN101568544B (zh) * 2006-10-27 2016-10-26 西格诺药品有限公司 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
CN103189360A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
IL189276A (en) 2012-07-31
TW200813060A (en) 2008-03-16
US20080139569A1 (en) 2008-06-12
AU2006285142A1 (en) 2007-03-08
EA200800716A1 (ru) 2008-08-29
PL1924585T3 (pl) 2012-08-31
EA014164B1 (ru) 2010-10-29
IL189276A0 (en) 2008-08-07
DK1924585T3 (da) 2012-02-27
TNSN08059A1 (en) 2009-07-14
RS52318B (en) 2012-12-31
CR9723A (es) 2008-06-18
ZA200801890B (en) 2009-11-25
ECSP088209A (es) 2008-06-30
HRP20120073T1 (hr) 2012-07-31
MA30000B1 (fr) 2008-12-01
UY29771A1 (es) 2007-03-30
BRPI0615259A2 (pt) 2011-05-17
UA91716C2 (ru) 2010-08-25
HK1123794A1 (en) 2009-06-26
PT1924585E (pt) 2012-01-19
EP1924585A1 (en) 2008-05-28
WO2007027525A1 (en) 2007-03-08
ATE531717T1 (de) 2011-11-15
KR20080050577A (ko) 2008-06-09
ES2375841T3 (es) 2012-03-06
CA2619284C (en) 2014-04-29
CN101253176B (zh) 2012-04-18
JP2009506116A (ja) 2009-02-12
EP1924585B1 (en) 2011-11-02
AR057099A1 (es) 2007-11-14
JP5063600B2 (ja) 2012-10-31
US7683062B2 (en) 2010-03-23
SI1924585T1 (sl) 2012-09-28
CN101253176A (zh) 2008-08-27
AU2006285142B2 (en) 2012-06-14
CA2619284A1 (en) 2007-03-08
CY1112317T1 (el) 2015-12-09
KR20130087059A (ko) 2013-08-05
NZ566087A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
NO20081365L (no) Ny krystallinsk form av et pyridazino[4,5-b]indolderivat
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
TW200716589A (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
NO2013017I1 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt, en forløper eller derivat, for eksempel ekstrometorfanhydrobromid og spesielt dekstrometorfanhydrobromid monohydrat; og (b) quinidin eller etfarmasøytisk akseptabelt salt, en forløper eller derivat derav, for eksempel quinidin og spesielt quinidinsulfat dihydrat
WO2004056827A3 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
CY1111767T1 (el) Υδρογονωμενα παραγωγα βενζο[c]θειοφαινιου ως ανοσορρυθμιστες
WO2002050061A8 (en) Piperazine derivatives for treatment of bacterial infections
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
NO2012006I2 (no) Telaprevir og enhver terapeutisk ekvivalent form derav som er beskyttet av basispatentet, slik som farmasøytisk akseptable salter og/eller solvater av telaprevir eller solvater av slike salter
CY1106606T1 (el) Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv
ECSP055780A (es) Derivados de indol utiles para el tratamiento de enfermedades
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
WO2002009650A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
ECSP055844A (es) Nuevos compuestos triciclicos
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
NO20056178L (no) CCI-779 lyofiliserte formuleringer
NO20044501L (no) [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
CY1108246T1 (el) ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ
WO2002013760A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
NO20080033L (no) Kinolinderivater som NK3-antagonister
NO20043834L (no) Farmasoytisk sammensetning omfattende N-((1-N-butyl-4-piperidinyl)metyl-3,4-dihydro-2H-(1,3)-oksazino(3,2-A)indol-l0-karboksyamid eller salter og fremgangsmate derfor omfattende torr granulering
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application